Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts

Abstract

COX-2 inhibition can extend the effectiveness of VEGFR inhibition. This effect is dependent on the timing of therapy. Clinical trials combining Su and COX-2 inhibitors should be considered as a means delaying time to progression on sunitinib in patients with metastatic cRCC.